Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Want to maximize your rewards? Discover what credit card has the highest rewards and make your spending work for you.
25,748 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
As markets wobble in mid-2026, a trio of NYSE dividend names stands out for safety and income. They combine durable c...
A quiet pivot from consumer devices to AI infrastructure has propelled this former smartphone maker into the spotligh...
Bitcoin faces a looming quantum threat as experts warn Q-Day could arrive around 2030. Galaxy Digital's up-to-$5 mill...
Regulators weigh new crypto rules as quantum risk looms in 2026. CryptoQuant founder Ki Young Ju’s idea to freeze dor...
In a world of hot bets and fast trades, one blue-chip name stands out as a potential core holding. Learn why Johnson ...
Palantir sits around $130 as Michael Burry’s $46 valuation challenge re-emerges, forcing a sharper look at growth, ma...
A confidential settlement in Maryland ends a high-profile dispute over HeLa cell patents and profits, signaling a new...
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Ethereum rebounded from February lows but remains trapped under major moving averages and a descending structure. Thi...
The Jets ETF has breached critical chart support, suggesting airline stocks face risks beyond rising fuel costs. Tech...
Ethereum shares edged higher after a leading asset manager introduced a US-traded staked ETH product. A prominent ana...